chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Covid breakthrough. I started feeling ill that morning on 3/22/2022. It worse during the day. By the end of the day, I had a fever and was kind of shaking. I was also having body aches. The congestion was mostly upper respiratory. As time went on that got better but the other symptoms got worse. I went to the drive through at my doctors office to take a covid and flu test and it came back positive and negative for the flu. My primary care said I qualified for paxlovid, its a 5 day regimen. My symptoms peaked halfway through the regimen. I continued to have fever and congestion. By Thursday, my congestion dropped in to my lungs. My symptoms got better by Saturday 3/26/2022. Now all I have is a cough.
Client Broke out in a rash all over his body a few hours after immunizations were given. He was at school at this time. He also was feeling nauseated but no emesis. was not having problems breathing at this time. This is reported to me by the school nurse.
After taking the 3rd pill of oral vaccine, patient developed nausea, vomiting, intermittent abdominal cramping.
Allergy; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) for a sponsored program.  An elderly male patient received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose number unknown, single for covid-19 immunisation. Relevant medical history included: "EPISTAXIS (nose bleeds)", start date: Dec2021 (unspecified if ongoing), notes: nose bleeds.; "Allergy" (unspecified if ongoing), notes: (pneumonia shot). The patient's concomitant medications were not reported. The following information was reported: HYPERSENSITIVITY (non-serious), outcome "unknown", described as "Allergy".  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
7/9/04-received vaccine 7/10/04 and 7/11/04 noted headache 7/12/04 seen in office per Dr-No fever. Site hot and reddened-sx have improved from previous day no treatment at this time. Pt did not inform Dr of previous adverse reaction
Painful swelling to left cheek and lips about a day after having fever from COVID vaccine. Seen by urgent care twice for presumed cold sore, saw Dr.  for continued and worsening symptoms and diagnosed with shingles.
Fever of 102°, muscle aches, body chills, shivering, headache, intense fatigue
Hot to touch at injection site, lots of swelling at injection site, itching at injection site.
I have a lot of aches and pains and I noticed it a little bit more than normal the next day. Also, I have COPD and I noticed it was harder to breath when I laid down.
Loss of taste; Loss of smell; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of AGEUSIA (Loss of taste) and ANOSMIA (Loss of smell) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced AGEUSIA (Loss of taste) and ANOSMIA (Loss of smell). At the time of the report, AGEUSIA (Loss of taste) and ANOSMIA (Loss of smell) outcome was unknown. Not provided.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications reported by investigator  No treatment medications provided by the reporter.
pt recvd vax 14SEP94 & presented to office on 20OCT94 c/o pain & swelling over lt parotid gland & lt sl gland; sx first noted 18OCT94; t98.8 oral; dx acute parotitis w/reactive lymphadenitis put on Cephalexin 250mg tid, APAP & warm compres;
injection site is swollen (size of a fig); injection site is itchy; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE SWELLING (injection site is swollen (size of a fig)) and INJECTION SITE PRURITUS (injection site is itchy) in a 71-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 015M20A) for COVID-19 vaccination.     The patient's past medical history included No adverse event.  On 09-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form.   On 17-Feb-2021, the patient experienced VACCINATION SITE SWELLING (injection site is swollen (size of a fig)) and INJECTION SITE PRURITUS (injection site is itchy).   At the time of the report, VACCINATION SITE SWELLING (injection site is swollen (size of a fig)) and INJECTION SITE PRURITUS (injection site is itchy) outcome was unknown.      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   Concomitant product use was not provided by the reporter. No treatment information was provided.
This spontaneous report as received from a healthcare worker refers to a 12 month old male infant without pertinent medical history, drug reactions or allergies. On 05-MAR-2014, the patient was vaccinated with a dose of PROQUAD (Merck), 0.5 ml, subcutaneous in the thigh (dose, lot number and expiration date were not reported). Secondary therapies included VAQTA, the same day (on 05-MAR-2014) (dose, route, lot number and expiration date were not reported) on the same tight but different location on the tight. On 14-MAR-2014, the patient developed a fever and then a measles "like rash", all over the body of the patient on 17-MAR-2014. Rash and fever were not better. At the time of the report, the patient had not recovered from fever and measles like rash. Patient received as treatment for fever TYLENOL. The physician was running some labs but healthcare worker was not sure what they were. It was reported that patient's parent sought medical attention by contacty the physcian's office. Additonal information has been requested.
Pt c/o inability to lift l/arm, redness @ site.  Swollen whol top of arm, c/o pain at inject site to l/arm.
This spontaneous case was reported by a consumer and describes the occurrence of SCIATIC NERVE NEUROPATHY (Sciatic nerve problems) in an adult male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. Co-suspect product included non-company product ADALIMUMAB (HUMIRA) solution for injection for Plaque psoriasis. No Medical History information was reported. In 2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. In 2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form and first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. In June 2022, received fourth dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) at an unspecified dose. On an unknown date, the patient experienced SCIATIC NERVE NEUROPATHY (Sciatic nerve problems). At the time of the report, SCIATIC NERVE NEUROPATHY (Sciatic nerve problems) outcome was unknown. No concomitant medications were reported. It was unknown if the patient was enrolled in a COVID-19 vaccine trial. The reporter causality for an event of sciatic nerve problems with adalimumab (Humira, solution for injection in prefilled pen) was provided as no reasonable possibility. No treatment medications were reported.
pain around injection site happened after 1st dose; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 32 year-old male patient received bnt162b2 (BNT162B2), administered in arm right, administration date 31Jul2021 (Lot number: EW0173) at the age of 32 years as dose 1, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: VACCINATION SITE PAIN (non-serious) with onset 22Aug2021, outcome "recovered" (2021), described as "pain around injection site happened after 1st dose". Therapeutic measures were not taken as a result of vaccination site pain.  No follow-up attempts are possible. No further information is expected.
Chills and Fever of 101.9 at its highest. It started on the evening that I received the vaccine.  My fever broke at 11pm the next day.  I have bruising at the vaccine site and have redness below the site.
c/o strange sensation (numbness, loss of sensation, pain radiating from lt foot to lt torso to rt side of face);seen by neurologist;adm to hosp 28OCT98; dx ADEM;
Hot Hypertensive (BP checked 6 times, elevated all times).   Given Juice and crackers, felt cooler and better after sitting and eating
Rash near injection site with redness and itch reappeared on day 8 post vaccine of first Moderna COVID-19 vaccine.  Patch was approximately 3-4 inches in diameter was slightly warm to touch.  Raised rash was noticed and photograph was collected if interested. Reporting via phone app stopped after day 7.
pt recv vax & p/vax pt lt arm went into a spasm, pt collapsed on table, body became limp,legs tight & pt fainted;pt was not hosp;MD reported other poss etiological factors include shot anxiety;poss vasovagal response;
Broke out in an unspecified rash; This is a spontaneous report from a contactable consumer based on the information received by Pfizer from Merck & Co., Inc. (Case Number: 01530794). A patient of unspecified age and gender received pneumococcal 13-val conj vac (dipht crm197 protein) (PREVNAR 13), via an unspecified route of administration on 10Jul2015 at single dose for immunization. The patient's medical history and concomitant medications were not reported. The patient experienced broke out in an unspecified rash on 10Jul2015 with outcome of unknown.    No follow-up attempts are possible; information about lot/batch number cannot be obtained.
flu like symptoms; diarrhea; nausea; body aches; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of INFLUENZA LIKE ILLNESS (flu like symptoms), DIARRHOEA (diarrhea), NAUSEA (nausea) and PAIN (body aches) in a 43-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 023M20A and 013L20A) for COVID-19 vaccination.     The patient's past medical history included No adverse event.   On 19-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 25-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 25-Feb-2021, the patient experienced INFLUENZA LIKE ILLNESS (flu like symptoms), DIARRHOEA (diarrhea), NAUSEA (nausea) and PAIN (body aches). On 26-Feb-2021, INFLUENZA LIKE ILLNESS (flu like symptoms), DIARRHOEA (diarrhea), NAUSEA (nausea) and PAIN (body aches) had resolved. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Treatment drugs are Advil, Tylenol, Aleve, Excedrin, Motrin   This case was linked to -MODERNATX, INC.-MOD-2021-079361 (E2B Linked Report).   Most recent FOLLOW-UP information incorporated above includes: On 19-May-2021: New event added; Sender's Comments:  -MODERNATX, INC.-MOD-2021-079361:1st dose
Several hours after getting my Covid vaccine JJ, my heart started racing.  It was beating between 90-110 beats per minutes for approximately 24 hours!!!   I did not go to a doctor or hospital.  I have no known heart condition.  I was also achy during that period.
received daptacel past the expiration with no reported adverse event; Initial information received on 12-Jul-2023 regarding an unsolicited valid non-serious case received from a physician.  This case is linked to cases 2023SA213495, 2023SA213484, 2023SA214480 and 2023SA213445.  This case involves a 6 years old patient of an unknown gender who received diphtheria-15/tetanus/5 AC pertussis vaccine [Daptacel] past the expiration with no reported adverse event.  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. Concomitant medications included polio vaccine inact 3V (VERO) (Ipol Polio Vaccine) for Prophylactic vaccination.  On 03-May-2023, the patient received a dose of 0.5 ml (dose 5) once of suspect diphtheria-15/tetanus/5 AC pertussis vaccine (Suspension for injection) (lot: C5829AA; expiry date: 01-May-2023; strength: standard) via intramuscular route in unknown administration site for Immunization.   On 03-May-2023 the patient received daptacel past the expiration with no reported adverse event (expired product administered) (latency: same day).  It was reported, "Physician is reporting that 6 pediatric patients have received DAPTACEL past the expiration date and caller is looking for re-vaccination information. Physician reports that due to a "unscrupulous employee, who has since been fired", 6 children received DAPTACEL vaccines after expiration date. He states that 8 days ago, a box of DAPTACEL was opened and noted to be expired. That caused staff to look back at doses of DAPTACEL given after 01-May-2023 (DAPTACEL expiration date). That is when the administration of expired doses was discovered."   Action taken was not applicable.  At time of reporting, the outcome was Unknown for the event.   This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the guidelines. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Received a subcutaneous injection, instead of intramuscular; Badly bruised arm; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE BRUISING (Badly bruised arm) and INCORRECT ROUTE OF PRODUCT ADMINISTRATION (Received a subcutaneous injection, instead of intramuscular) in a 76-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 029L20A and 029L20A) for COVID-19 vaccination.     Concurrent medical conditions included Pemphigoid (Mucous membrane pemphigoid) since June 2015, Atrial fibrillation since February 2015, COPD since December 2018, Adhesive tape allergy, Hypertension since 2019, High cholesterol since 2019, Gout since 2009, Thyroid disorder since 2017, Diabetes since 2007, Allergy to antibiotic (Levaquin), Drug allergy (Vasotec), Drug allergy (Calan SR), Drug allergy (Lipitor) and Allergy to antibiotic (Doxycycline). Concomitant products included APIXABAN (ELIQUIS) for Atrial fibrillation, INSULIN GLARGINE (LANTUS) for Diabetes, FEBUXOSTAT (ULORIC) for Gout, PRAVASTATIN for Hyperlipidemia, DILTIAZEM and FUROSEMIDE (LASIX [FUROSEMIDE]) for Hypertension, CARVEDILOL for Hypertension and COPD, MYCOPHENOLATE MOFETIL and DAPSONE for Pemphigoid, LEVOTHYROXINE SODIUM (LEVOXYL) for Thyroid disorder, ACETYLSALICYLIC ACID (BABY ASPIRIN) and VITAMIN D3 for an unknown indication.   On 21-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 18-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Subcutaneous) dosage was changed to 1 dosage form. In February 2021, the patient experienced VACCINATION SITE BRUISING (Badly bruised arm). On 18-Feb-2021, the patient experienced INCORRECT ROUTE OF PRODUCT ADMINISTRATION (Received a subcutaneous injection, instead of intramuscular). On 18-Feb-2021, INCORRECT ROUTE OF PRODUCT ADMINISTRATION (Received a subcutaneous injection, instead of intramuscular) had resolved. At the time of the report, VACCINATION SITE BRUISING (Badly bruised arm) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Subcutaneous), the reporter did not provide any causality assessments.   Treatment information was not provided.   Most recent FOLLOW-UP information incorporated above includes: On 06-Apr-2021: Added medical history and concomitant medications. Updated lot number and event.; Reporter's Comments: This report refers to a case of incorrect route of product administration for mRNA-1273 (lot # 024M20A) with no associated AEs reported.
9-29-16-Around 4:00 PM patient developed temperature of 100.3F axillary. 9-30-16-Around 9:00 AM patient developed pain, swelling, redness and warmth at injection site-left deltoid.
Pt vaccinated with Mumpsvax developed pancreatitis. At time of report, liver function test were normal. Additional info being requested.
It started in the right side of my neck/throat tightness and swelling it moved up into jaw, mouth, cheek,nose, eye, ear. very slight swelling , was numb. The swelling in my throat did cause some breathing problems , but, I had read this was a possible normal reaction so I did not notify people there. I also have had antifilactic reactions in the past and knew this one was not life threatening. I took three beneydryl once I got home and after about three hours the progression subsided.  Numbness and swelling was gone in 24 hours, but, I am still having nausea, body pain and headaches, fatigue.
No adverse event; Given vaccine which was beyond the 30 day use by date; Given vaccine which underwent temperture excursion; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Given vaccine which was beyond the 30 day use by date), PRODUCT TEMPERATURE EXCURSION ISSUE (Given vaccine which underwent temperture excursion) and NO ADVERSE EVENT (No adverse event) in a 47-year-old patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 083B22A) for COVID-19 vaccination.     No Medical History information was reported.    On 31-Aug-2022, the patient received fourth dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Intramuscular) 1 dosage form. In August 2022, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Given vaccine which underwent temperture excursion). On 31-Aug-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (Given vaccine which was beyond the 30 day use by date). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Given vaccine which was beyond the 30 day use by date), PRODUCT TEMPERATURE EXCURSION ISSUE (Given vaccine which underwent temperture excursion) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Intramuscular), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for EXPIRED PRODUCT ADMINISTERED (Given vaccine which was beyond the 30 day use by date) and PRODUCT TEMPERATURE EXCURSION ISSUE (Given vaccine which underwent temperture excursion).    No concomitant products reported. It was reported that the lot number underwent temperature excursion on 15 to 17 Aug 2022 and was administered to the patient post temperature excursion.  No treatment products reported.
1) Swollen and painful breasts (under each nipple) with slight redness. 2) Swollen and painful nodes under both arms (3-5 swollen nodes in each armpit).
super dizzy; body aches; Headache; This spontaneous case was reported by a consumer and describes the occurrence of DIZZINESS (super dizzy), MYALGIA (body aches) and HEADACHE (Headache) in a 51-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 006C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 23-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 24-Apr-2021, the patient experienced MYALGIA (body aches) and HEADACHE (Headache). On 26-Apr-2021, the patient experienced DIZZINESS (super dizzy). On 24-Apr-2021, MYALGIA (body aches) and HEADACHE (Headache) had resolved. At the time of the report, DIZZINESS (super dizzy) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No treatment medication were reported. No concomitant medication were reported
Patient is a 37-year-old male who developed hives within 5-6 hrs after receiving anthrax # 3 administered on 3 Sept 2003. States he had no problems with the first and second anthrax.  Pt reported that he had a "significant" local reaction and diffuse hives on legs, and torso. Denied any respiratory, cardiovascular or gastrointestinal problems. States hives cleared with in 24 hrs with Benedryl and had not had any recurrence of the hives or any residual effects. States he has never had hives before and he denied any new soaps, detergents, foods or medication. Has received other vaccines since administration of anthrax without any problems.
After RN administered vaccine, when she removed the "needle retractable safety syringe with needle" the syringe detached from needle leaving needle with hub in arm. RN removed the needle from arm. Patient stated she felt a drop go into her eye.
Patient had localized swelling at the site of injection. The arm was roughly 1/4 bigger than normal size.
Patient administered full 3rd dose of vaccine rather than 50mcg dose (patient not immunocompromised); This spontaneous case was reported by a pharmacist and describes the occurrence of ACCIDENTAL OVERDOSE (Patient administered full 3rd dose of vaccine rather than 50mcg dose (patient not immunocompromised)) in a 48-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 029H21B, 019B21A and 047B21A) for COVID-19 vaccination.     No Medical History information was reported.   On 25-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 22-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 16-Dec-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 16-Dec-2021, the patient experienced ACCIDENTAL OVERDOSE (Patient administered full 3rd dose of vaccine rather than 50mcg dose (patient not immunocompromised)). On 16-Dec-2021, ACCIDENTAL OVERDOSE (Patient administered full 3rd dose of vaccine rather than 50mcg dose (patient not immunocompromised)) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications reported. No treatment reported
Initial report received from a non-health care profession on 05 December 2013.  Two patients, whose age, medical history and concomitant medications were not reported, had received a dose of FLUZONE HD (lot number, route and size of vaccination were not reported) on 04 December 2013. On 03 December 2013, reporter stated that had 2 patients who had reaction following FLUZONE HD vaccination. A female patient had a 4 in open wound at injection site. At the time of this report the outcome of adverse event was unknown. Documents held by sender: none
MD called & stated pt had febrile react w/sz secondary to MMR 9 days post vax;
A report has been received from a Health Professional concerning a, Female subject, who had been receiving FLUMIST QUADRIVALENT (Intranasal), 0.2 Millilitres, unknown. FLUMIST QUADRIVALENT (intranasal) started on 21-Jan-2016. It was reported that patient was administered expired FLUMIST QUADRIVALENT. The outcome of the event of administered expired FLUMIST QUADRIVALENT was unknown. The report was considered to be non-serious.
As soon as the vaccine was administered the site started to swell up. Patient felt sweating on forehead and felt faint. He collapsed and fell to the ground. We called 911 and administered BENADRYL 50mg injectable. He came to and went to the hospital ER.